Scotiabank raised the firm’s price target on Argenx (ARGX) to $796 from $715 and keeps an Outperform rating on the shares. The company’s Q2 results included a “strong” top-line beat for Vyvgart across myasthenia gravis, MG, and Chronic inflammatory demyelinating polyradiculoneuropathy, CIDP, markets in and outside the U.S., the analyst tells investors. The firm notes it is yet to be determined if this momentum continues despite upcoming competition in the sector.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx price target raised to $775 from $750 at Evercore ISI
- Argenx price target raised to $880 from $829 at BofA
- Argenx price target raised to $778 from $708 at Oppenheimer
- Argenx price target raised to $788 from $680 at Baird
- Argenx Se’s Strong Market Position and Impressive Financial Performance Drive Buy Rating